Partners HealthCare has co-led a series A round for ZielBio to drive forward the development of a cancer treatment based on research at University of Virginia.

ZielBio, a US-based biotechnology spinout of University of Virginia, closed a $25.1m series A round on Thursday co-led by Partners Innovation Fund (PIF), the investment arm of health system Partners HealthCare, and Morningside Venture Investments.
Founded in 2012 as iTiHealth, ZielBio has built a platform called Zielfind that combines functional, high-throughput screening with data analytics to identify high-value targets for therapeutics.
The company is initially focusing on ZB131, an antibody against cell surface plectin (CSP), a target highly…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in